Heplisav-B™ (hepatitis B vaccine) – New drug approval
November 9, 2017 – Dynavax announced the FDA approval of Heplisav-B (hepatitis B vaccine [recombinant] adjuvanted), for the prevention of infection caused by all known subtypes of hepatitis B virus.
Download PDF
